Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAb-Trap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL)
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenzhi Tian, Qiying Lu, Heming He(State Nuclear Power Technology Company (China)), Hongmei Jing(Peking University), Yongping Song(First Affiliated Hospital of Zhengzhou University), Fei Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Mingzhi Zhang(Chinese Academy of Sciences), Wenyu Li(Shenyang Agricultural University), Zhen Wang(Huanghuai University), Junyuan Qi(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianliang Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhiming Li(Anhui Medical University), Siman Gao(Shanghai Jiao Tong University), Huizi Ma(Capital Medical University)
Cited by 5
Related Papers
Targeting CD47 for cancer immunotherapy
|Journal of Hematology & Oncology|2021|342
Association analyses identify six new psoriasis susceptibility loci in the Chinese population
|Nature Genetics|2010|317
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
The thermal and electrical properties of the promising semiconductor MXene Hf2CO2
|Scientific Reports|2016|276
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256